Precision Target Medicine Articles & Analysis
232 news found
"There's also a growing movement away from antibiotics and toward precision medicine when it comes to treating disease in animals—whether companion pets or livestock." ...
ByBioVenic
Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. In dermatology, new methods for treating benign epidermal lesions are ...
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the number and kind ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
CD Formulation, a leader in biotechnological innovation, is advancing the field of targeted drug delivery with its customized metal-organic frameworks (MOFs) services. The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost ...
“Working side-by-side with Boundless Bio and SOPHiA GENETICS, Precision for Medicine has generated a novel and seamless platform unlike any other that enables a new model for clinical trial testing,” said Darren Davis, PhD, Senior Vice President, Precision for Medicine. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal ...
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer ...
ByTempus
This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision medicine. Epigenetics is a field of genetics that delves into the influence of chemical modifications within the genome ...
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
ByCELLINK
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge protein drug design. ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
CD Genomics, a global leader in genomic and bioinformatics solutions, is pleased to announce the official launch of its Viral Metagenomic Sequencing service. This state-of-the-art offering represents a major advancement in the field of pathogen research and promises to provide unparalleled insights into viral communities. Viruses, being the most abundant entities on our planet, play a pivotal ...
HLA typing, the process of identifying specific alleles within the HLA genes, is indispensable for personalized medicine, disease association studies, and achieving successful transplant outcomes. ...
Investigation of Complex Genomic Regions: LAA empowers scientists to delve into complex genomic regions that hold critical biological insights, such as regulatory elements, disease-related genes, and repetitive sequences. 3. Targeted Gene Analysis: Offering an economical and efficient solution for targeted gene analysis, LAA proves ideal for studying specific ...
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. This innovative advancement promises to revolutionize the field, providing researchers in the life sciences with an unprecedented opportunity to gain comprehensive insights into the complexity ...
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise ...